Walter Wahli

List of Publications by Year
in descending order

298 papers	39,335 citations	2544 96 h-index	2747 192 g-index
308 all docs	308 docs citations	308 times ranked	33304 citing authors

#	Article	IF	Citations
1	Integrative study of diet-induced mouse models of NAFLD identifies PPARÎ± as a sexually dimorphic drug target. Gut, 2022, 71, 807-821.	12.1	26
2	Adipose-Specific PPARÎ± Knockout Mice Have Increased Lipogenesis by PASKâ€“SREBP1 Signaling and a Polarity Shift to Inflammatory Macrophages in White Adipose Tissue. Cells, 2022, 11, 4.	4.1	33
3	Role of Dietary Supplements and Probiotics in Modulating Microbiota and Bone Health: The Gut-Bone Axis. Cells, 2022, 11, 743.	4.1	36
4	Nuclear HMGB1 protects from nonalcoholic fatty liver disease through negative regulation of liver X receptor. Science Advances, 2022, 8, eabg9055.	10.3	7
5	The hepatocyte insulin receptor is required to program the liver clock and rhythmic gene expression. Cell Reports, 2022, 39, 110674.	6.4	12
6	PPARs as Key Mediators in the Regulation of Metabolism and Inflammation. International Journal of Molecular Sciences, 2022, 23, 5025.	4.1	7
7	The Loss of PPARÎ± in Adipocytes Induces Lipogenesis via the PASKâ€SREBP1 Signaling Axis. FASEB Journal, 2022, 36, .	0.5	0
8	Invalidation of the Transcriptional Modulator of Lipid Metabolism PPARÎ²/Î´ in T Cells Prevents Age-Related Alteration of Body Composition and Loss of Endurance Capacity. Frontiers in Physiology, 2021, 12, 587753.	2.8	4
9	The pregnane X receptor drives sexually dimorphic hepatic changes in lipid and xenobiotic metabolism in response to gut microbiota in mice. Microbiome, 2021, 9, 93.	11.1	11
10	PPARs and Tumor Microenvironment: The Emerging Roles of the Metabolic Master Regulators in Tumor Stromalâ€“Epithelial Crosstalk and Carcinogenesis. Cancers, 2021, 13, 2153.	3.7	34
11	LRG1 Promotes Metastatic Dissemination of Melanoma through Regulating EGFR/STAT3 Signalling. Cancers, 2021, 13, 3279.	3.7	15
12	Roles of Estrogens in the Healthy and Diseased Oviparous Vertebrate Liver. Metabolites, 2021, 11, 502.	2.9	5
13	The PPARÎ²/Î´-AMPK Connection in the Treatment of Insulin Resistance. International Journal of Molecular Sciences, 2021, 22, 8555.	4.1	17
14	GDF15 mediates the metabolic effects of PPARÎ²/Î´ by activating AMPK. Cell Reports, 2021, 36, 109501.	6.4	41
15	Mechanistic definition of the cardiovascular mPGES-1/COX-2/ADMA axis. Cardiovascular Research, 2020, 116, 1972-1980.	3.8	16
16	Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells, 2020, 9, 1638.	4.1	76
17	Peroxisome Proliferator-Activated Receptors as Molecular Links between Caloric Restriction and Circadian Rhythm. Nutrients, 2020, 12, 3476.	4.1	15
18	Peroxisome Proliferator-Activated Receptors and Caloric Restrictionâ€"Common Pathways Affecting Metabolism, Health, and Longevity. Cells, 2020, 9, 1708.	4.1	39

#	Article	IF	Citations
19	PPARs and Microbiota in Skeletal Muscle Health and Wasting. International Journal of Molecular Sciences, 2020, 21, 8056.	4.1	50
20	Deficiency in fibroblast PPARÎ²/Î´ reduces nonmelanoma skin cancers in mice. Cell Death and Differentiation, 2020, 27, 2668-2680.	11.2	10
21	Exploring Extracellular Vesicles Biogenesis in Hypothalamic Cells through a Heavy Isotope Pulse/Trace Proteomic Approach. Cells, 2020, 9, 1320.	4.1	11
22	PPARÎ²/Î´ Agonism Upregulates Forkhead Box A2 to Reduce Inflammation in C2C12 Myoblasts and in Skeletal Muscle. International Journal of Molecular Sciences, 2020, 21, 1747.	4.1	10
23	Investigating the Role of PPARÎ²/Î´ in Retinal Vascular Remodeling Using PparÎ²/Î´-Deficient Mice. International Journal of Molecular Sciences, 2020, 21, 4403.	4.1	6
24	Hepatocyte-specific deletion of PparÎ± promotes NAFLD in the context of obesity. Scientific Reports, 2020, 10, 6489.	3.3	80
25	Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants. Biomolecules, 2020, 10, 1702.	4.0	79
26	The gut microbiota influences skeletal muscle mass and function in mice. Science Translational Medicine, 2019, 11, .	12.4	271
27	Pharmacological PPARÎ²/Î´ activation upregulates VLDLR in hepatocytes. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2019, 31, 111-118.	0.2	2
28	The Potential of the FSP1cre-Pparb/dâˆ'/âˆ' Mouse Model for Studying Juvenile NAFLD. International Journal of Molecular Sciences, 2019, 20, 5115.	4.1	2
29	Hepatic PPARÎ± is critical in the metabolic adaptation to sepsis. Journal of Hepatology, 2019, 70, 963-973.	3.7	53
30	The PPARâ€"microbiotaâ€"metabolic organ trilogy to fineâ€tune physiology. FASEB Journal, 2019, 33, 9706-9730.	0.5	46
31	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMÎ±) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	6.8	104
32	Exploiting vulnerabilities of cancer by targeting nuclear receptors of stromal cells in tumor microenvironment. Molecular Cancer, 2019, 18, 51.	19.2	57
33	Depletion of Gram-Positive Bacteria Impacts Hepatic Biological Functions During the Light Phase. International Journal of Molecular Sciences, 2019, 20, 812.	4.1	8
34	Collaborative Regulation of LRG1 by TGF-Î²1 and PPAR-Î²/Î´ Modulates Chronic Pressure Overloadâ€"Induced Cardiac Fibrosis. Circulation: Heart Failure, 2019, 12, e005962.	3.9	29
35	Pharmacological PPARÎ²/Î´ activation upregulates VLDLR in hepatocytes. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 111-118.	0.8	6
36	Selective deletion of PPARÎ²/Î´ in fibroblasts causes dermal fibrosis by attenuated LRG1 expression. Cell Discovery, 2018, 4, 15.	6.7	28

#	Article	IF	Citations
37	Peroxisome Proliferator Activated Receptor Gamma Controls Mature Brown Adipocyte Inducibility through Glycerol Kinase. Cell Reports, 2018, 22, 760-773.	6.4	86
38	ROS release by PPARÎ²/Î´-null fibroblasts reduces tumor load through epithelial antioxidant response. Oncogene, 2018, 37, 2067-2078.	5.9	14
39	Hepatic regulation of VLDL receptor by PPARÎ²/Î´ and FGF21 modulates non-alcoholic fatty liver disease. Molecular Metabolism, 2018, 8, 117-131.	6.5	77
40	Cyclooxygenase-2 Selectively Controls Renal Blood Flow Through a Novel PPARÎ²/Î´-Dependent Vasodilator Pathway. Hypertension, 2018, 71, 297-305.	2.7	32
41	Dual <scp>PPAR</scp>Î±/Î³ agonist saroglitazar improves liver histopathology and biochemistry in experimental <scp>NASH</scp> models. Liver International, 2018, 38, 1084-1094.	3.9	153
42	Insights into the role of hepatocyte PPARÎ± activity in response to fasting. Molecular and Cellular Endocrinology, 2018, 471, 75-88.	3.2	40
43	The Role of PPARÎ²/Î´ in Melanoma Metastasis. International Journal of Molecular Sciences, 2018, 19, 2860.	4.1	17
44	The OEA effect on food intake is independent from the presence of PPARÎ± in the intestine and the nodose ganglion, while the impact of OEA on energy expenditure requires the presence of PPARÎ± in mice. Metabolism: Clinical and Experimental, 2018, 87, 13-17.	3.4	11
45	Enteric Microbiotaâ€"Gutâ€"Brain Axis from the Perspective of Nuclear Receptors. International Journal of Molecular Sciences, 2018, 19, 2210.	4.1	21
46	Complementary intestinal mucosa and microbiota responses to caloric restriction. Scientific Reports, 2018, 8, 11338.	3.3	37
47	Insights into the Role of PPARÎ²/Î´ in NAFLD. International Journal of Molecular Sciences, 2018, 19, 1893.	4.1	42
48	Metronidazole Causes Skeletal Muscle Atrophy and Modulates Muscle Chronometabolism. International Journal of Molecular Sciences, 2018, 19, 2418.	4.1	45
49	Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome. Expert Opinion on Therapeutic Targets, 2017, 21, 333-348.	3.4	54
50	Roles of Peroxisome Proliferator-Activated Receptor Î²/Î´ in skeletal muscle physiology. Biochimie, 2017, 136, 42-48.	2.6	57
51	A Specific ChREBP and PPARÎ± Cross-Talk Is Required for the Glucose-Mediated FGF21 Response. Cell Reports, 2017, 21, 403-416.	6.4	99
52	PPARÎ³ Modulates Long Chain Fatty Acid Processing in the Intestinal Epithelium. International Journal of Molecular Sciences, 2017, 18, 2559.	4.1	43
53	Glucocorticoid receptor-PPARÎ± axis in fetal mouse liver prepares neonates for milk lipid catabolism. ELife, 2016, 5, .	6.0	37
54	Hepatic Fasting-Induced PPARÎ± Activity Does Not Depend on Essential Fatty Acids. International Journal of Molecular Sciences, 2016, 17, 1624.	4.1	8

#	Article	IF	Citations
55	Liver PPARÎ± is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut, 2016, 65, 1202-1214.	12.1	494
56	Transcriptional control of physiological and pathological processes by the nuclear receptor PPARÎ²/Î´. Progress in Lipid Research, 2016, 64, 98-122.	11.6	58
57	Heme-Regulated eIF2Î± Kinase Modulates Hepatic FGF21 and Is Activated by PPARÎ²/Î´ Deficiency. Diabetes, 2016, 65, 3185-3199.	0.6	31
58	High-fat diet modifies the PPAR-Î³ pathway leading to disruption of microbial and physiological ecosystem in murine small intestine. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5934-E5943.	7.1	180
59	Intestinal PPARÎ³ signalling is required for sympathetic nervous system activation in response to caloric restriction. Scientific Reports, 2016, 6, 36937.	3.3	20
60	Hepatic circadian clock oscillators and nuclear receptors integrate microbiome-derived signals. Scientific Reports, 2016, 6, 20127.	3.3	92
61	Peroxisome proliferator-activated receptor Î²/Î´ induces myogenesis by modulating myostatin activity.. Journal of Biological Chemistry, 2016, 291, 14391.	3.4	0
62	A trilogy of glucocorticoid receptor actions. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1115-1117.	7.1	15
63	â€œEvery day I dream ...â€•An interview with the Rwandan Health Minister. Swiss Medical Weekly, 2016, 146, w14316.	1.6	0
64	PPARÎ±Is Required for PPARÎ´Action in Regulation of Body Weight and Hepatic Steatosis in Mice. PPAR Research, 2015, 2015, 1-15.	2.4	38
65	Nuclear Hormone Receptors and Epidermal Differentiation. , 2015, , 91-106.		1
66	PPAR-Î²/Î´ activation promotes phospholipid transfer protein expression. Biochemical Pharmacology, 2015, 94, 101-108.	4.4	23
67	Inactivation of PPARÎ²/Î´ adversely affects satellite cells and reduces postnatal myogenesis. American Journal of Physiology - Endocrinology and Metabolism, 2015, 309, E122-E131.	3.5	16
68	PPARÎ²/Î´ ameliorates fructose-induced insulin resistance in adipocytes by preventing Nrf2 activation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1049-1058.	3.8	21
69	Nuclear receptor peroxisome proliferator activated receptor (PPAR) Î²/Î´ in skin wound healing and cancer. European Journal of Dermatology, 2015, 25, 4-11.	0.6	18
70	Authorship in scientific publications: analysis and recommendations. Swiss Medical Weekly, 2015, 145, w14108.	1.6	30
71	Absence of Intestinal PPARÎ³ Aggravates Acute Infectious Colitis in Mice through a Lipocalin-2â€"Dependent Pathway. PLoS Pathogens, 2014, 10, e1003887.	4.7	34
72	The emerging role of N rf2 in dermatotoxicology. EMBO Molecular Medicine, 2014, 6, 431-433.	6.9	11

#	Article	IF	Citations
73	Src is activated by the nuclear receptor peroxisome proliferatorâ€activated receptor Î²/Î´ in ultraviolet radiationâ€induced skin cancer. EMBO Molecular Medicine, 2014, 6, 80-98.	6.9	50
74	The coactivator PGC-1Î± regulates skeletal muscle oxidative metabolism independently of the nuclear receptor PPARÎ²/Î´ in sedentary mice fed a regular chow diet. Diabetologia, 2014, 57, 2405-2412.	6.3	17
75	PPARÎ²/Î´ prevents endoplasmic reticulum stress-associated inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism. Diabetologia, 2014, 57, 2126-2135.	6.3	83
76	Myostatin Augments Muscle-Specific Ring Finger Protein-1 Expression Through an NF-kB Independent Mechanism in SMAD3 Null Muscle. Molecular Endocrinology, 2014, 28, 317-330.	3.7	36
77	PPARÎ²/Î´ attenuates palmitate-induced endoplasmic reticulum stress and induces autophagic markers in human cardiac cells. International Journal of Cardiology, 2014, 174, 110-118.	1.7	58
78	PPARÎ²/Î´ is not required by PGCâ€1Î± to enhance skeletal muscle oxidative metabolism (1164.3). FASEB Journal, 2014, 28, 1164.3.	0.5	0
79	Nutrigenomic foods. Nutrafoods, 2013, 12, 3-12.	0.5	7
80	Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARÎ²/Î´-null mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1241-1248.	3.8	37
81	Role of the circadian clock gene Per2 in adaptation to cold temperature. Molecular Metabolism, 2013, 2, 184-193.	6.5	92
82	The Peroxisomal Enzyme L-PBE Is Required to Prevent the Dietary Toxicity of Medium-Chain Fatty Acids. Cell Reports, 2013, 5, 248-258.	6.4	45
83	Contributions of peroxisome proliferator-activated receptor Î²/Î´ to skin health and disease. Biomolecular Concepts, 2013, 4, 53-64.	2.2	10
84	Studying Wound Repair in the Mouse. Current Protocols in Mouse Biology, 2013, 3, 171-185.	1.2	26
85	PPARÎ² Interprets a Chromatin Signature of Pluripotency to Promote Embryonic Differentiation at Gastrulation. PLoS ONE, 2013, 8, e83300.	2.5	7
86	Lack of Smad3 signaling leads to impaired skeletal muscle regeneration. American Journal of Physiology - Endocrinology and Metabolism, 2012, 303, E90-E102.	3.5	42
87	Peroxisome Proliferator-activated Receptor Î²/Î´ Induces Myogenesis by Modulating Myostatin Activity. Journal of Biological Chemistry, 2012, 287, 12935-12956.	3.4	28
88	The nuclear hormone receptor PPARÎ³ counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells. Nature Communications, 2012, 3, 1077.	12.8	73
89	La activaciÃ³n de receptor activado por proliferadores peroxisÃ³micos Î²/Î´ mejora la resistencia a insulina inducida por IL-6 en cÃ©lulas hepÃ¡ticas. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2012, 24, 275-283.	0.8	0
90	PPARs at the crossroads of lipid signaling and inflammation. Trends in Endocrinology and Metabolism, 2012, 23, 351-363.	7.1	537

#	Article	IF	Citations
91	GW501516-activated PPARÎ²/Î´ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation. Cell and Bioscience, 2012, 2, 34.	4.8	63
92	PPARÎ²/Î´ affects pancreatic Î² cell mass and insulin secretion in mice. Journal of Clinical Investigation, 2012, 122, 4105-4117.	8.2	45
93	Hepatic Deficiency in Transcriptional Cofactor TBL1 Promotes Liver Steatosis and Hypertriglyceridemia. Cell Metabolism, 2011, 13, 389-400.	16.2	49
94	Sex differences in nuclear receptor-regulated liver metabolic pathways. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 964-973.	3.8	60
95	PPARÎ²/Î´ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2011, 1811, 59-67.	2.4	66
96	New insights into the role of PPARs. Prostaglandins Leukotrienes and Essential Fatty Acids, 2011, 85, 235-243.	2.2	49
97	The inhibition of fat cell proliferation by n-3 fatty acids in dietary obese mice. Lipids in Health and Disease, 2011, 10, 128.	3.0	35
98	Smad3 signaling is required for satellite cell function and myogenic differentiation of myoblasts. Cell Research, 2011, 21, 1591-1604.	12.0	85
99	Smad3 Deficiency in Mice Protects Against Insulin Resistance and Obesity Induced by a High-Fat Diet. Diabetes, 2011, 60, 464-476.	0.6	123
100	Activation of Peroxisome Proliferatorâ€"Activated Receptor-Î²/-Î´ (PPAR-Î²/-Î´) Ameliorates Insulin Signaling and Reduces SOCS3 Levels by Inhibiting STAT3 in Interleukin-6â€"Stimulated Adipocytes. Diabetes, 2011, 60, 1990-1999.	0.6	64
101	Proline- and acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-activated receptor Î± (PPARÎ±) activity. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4794-4799.	7.1	63
102	Beneficial effects of combinatorial micronutrition on body fat and atherosclerosis in mice. Cardiovascular Research, 2011, 91, 732-741.	3.8	5
103	Mechanisms of the Anti-Obesity Effects of Oxytocin in Diet-Induced Obese Rats. PLoS ONE, 2011, 6, e25565.	2.5	211
104	Cyclooxygenase-2 Controls Energy Homeostasis in Mice by de Novo Recruitment of Brown Adipocytes. Science, 2010, 328, 1158-1161.	12.6	401
105	PPAR Modulation of Kinase-Linked Receptor Signaling in Physiology and Disease. Physiology, 2010, 25, 176-185.	3.1	19
106	Peroxisome proliferator-activated receptor Î²/Î´: a master regulator of metabolic pathways in skeletal muscle. Hormone Molecular Biology and Clinical Investigation, 2010, 4, 565-573.	0.7	3
107	PPARÎ±, A Key Regulator of Hepatic Energy Homeostasis in Health and Disease. , 2010, , 305-315.		1
108	A Concerted Kinase Interplay Identifies PPARÎ³ as a Molecular Target of Ghrelin Signaling in Macrophages. PLoS ONE, 2009, 4, e7728.	2.5	34

#	Article	IF	Citations
109	Regulation of epithelialâ€“mesenchymal IL-1 signaling by PPARÎ²/Î´ is essential for skin homeostasis and wound healing. Journal of Cell Biology, 2009, 184, 817-831.	5.2	97
110	Fatty Acid Synthesis and PPARÎ± Hand in Hand. Chemistry and Biology, 2009, 16, 801-802.	6.0	14
111	Atherosclerotic mice exhibit systemic inflammation in periadventitial and visceral adipose tissue, liver, and pancreatic islets. Atherosclerosis, 2009, 207, 360-367.	0.8	65
112	Sumoylated PPARÎ± mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice. Journal of Clinical Investigation, 2009, 119, 3138-3148.	8.2	102
113	Regulation of epithelialâ€“mesenchymal IL-1 signaling by PPARÎ²/Î´ is essential for skin homeostasis and wound healing. Journal of Experimental Medicine, 2009, 206, i6-i6.	8.5	0
114	Loss of Egg Yolk Genes in Mammals and the Origin of Lactation and Placentation. PLoS Biology, 2008, 6, e63.	5.6	122
115	Activation of Peroxisome Proliferatorâ€“Activated Receptor Î²/Î´ Inhibits Lipopolysaccharide-Induced Cytokine Production in Adipocytes by Lowering Nuclear Factor-ÎºB Activity via Extracellular Signalâ€“Related Kinase 1/2. Diabetes, 2008, 57, 2149-2157.	0.6	108
116	PPARÎ³: Ally and Foe in Bone Metabolism. Cell Metabolism, 2008, 7, 188-190.	16.2	18
117	Peroxisome Proliferator-Activated Receptors Mediate Host Cell Proinflammatory Responses to<i>Pseudomonas aeruginosa</i>Autoinducer. Journal of Bacteriology, 2008, 190, 4408-4415.	2.2	137
118	PPAR Disruption: Cellular Mechanisms and Physiological Consequences. Chimia, 2008, 62, 340-344.	0.6	4
119	PPARs Mediate Lipid Signaling in Inflammation and Cancer. PPAR Research, 2008, 2008, 1-15.	2.4	91
120	Tissue Repair and Cancer Control through PPARs and Their Coregulators. , 2008, , 409-440.		0
121	The Nuclear Hormone Receptor Peroxisome Proliferator-Activated Receptor Î²/Î´ Potentiates Cell Chemotactism, Polarization, and Migration. Molecular and Cellular Biology, 2007, 27, 7161-7175.	2.3	60
122	Adipose Tissue Integrity as a Prerequisite for Systemic Energy Balance. Journal of Biological Chemistry, 2007, 282, 29946-29957.	3.4	38
123	The Endocrine Disruptor Monoethyl-hexyl-phthalate Is a Selective Peroxisome Proliferator-activated Receptor Î³ Modulator That Promotes Adipogenesis. Journal of Biological Chemistry, 2007, 282, 19152-19166.	3.4	294
124	Combined Simulation and Mutagenesis Analyses Reveal the Involvement of Key Residues for Peroxisome Proliferator-activated ReceptorÎ± Helix 12 Dynamic Behavior. Journal of Biological Chemistry, 2007, 282, 9666-9677.	3.4	33
125	Stage-specific Integration of Maternal and Embryonic Peroxisome Proliferator-activated Receptor Î´ Signaling Is Critical to Pregnancy Success. Journal of Biological Chemistry, 2007, 282, 37770-37782.	3.4	55
126	Association with Coregulators Is the Major Determinant Governing Peroxisome Proliferator-activated Receptor Mobility in Living Cells. Journal of Biological Chemistry, 2007, 282, 4417-4426.	3.4	42

#	Article	IF	Citations
127	Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 991-998.	2.4	153
128	Guiding Ligands to Nuclear Receptors. Cell, 2007, 129, 649-651.	28.9	38
129	The Interleukin-1 receptor antagonist is a direct target gene of PPARÎ± in liver. Journal of Hepatology, 2007, 46, 869-877.	3.7	66
130	Roles of the peroxisome proliferator-activated receptor (PPAR) Î± and Î²/Î´ in skin wound healing. International Congress Series, 2007, 1302, 45-52.	0.2	2
131	IL-13 induces expression of CD36 in human monocytes through PPARÎ³ activation. European Journal of Immunology, 2007, 37, 1642-1652.	2.9	83
132	Malignant Transformation of DMBA/TPA-Induced Papillomas and Nevi in the Skin of Mice Selectively Lacking Retinoid-X-Receptor Î± in Epidermal Keratinocytes. Journal of Investigative Dermatology, 2007, 127, 1250-1260.	0.7	78
133	Fat poetry: a kingdom for PPARÎ³. Cell Research, 2007, 17, 486-511.	12.0	127
134	Transcriptional Regulation of Metabolism. Physiological Reviews, 2006, 86, 465-514.	28.8	749
135	PPARÎ²/Î´ Regulates Paneth Cell Differentiation Via Controlling the Hedgehog Signaling Pathway. Gastroenterology, 2006, 131, 538-553.	1.3	98
136	PGC1Î± expression is controlled in skeletal muscles by PPARÎ², whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metabolism, 2006, 4, 407-414.	16.2	340
137	From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Progress in Lipid Research, 2006, 45, 120-159.	11.6	656
138	Integrating nuclear receptor mobility in models of gene regulation. Nuclear Receptor Signaling, 2006, 4, nrs.04010.	1.0	8
139	PPARs in fetal and early postnatal development. Advances in Developmental Biology (Amsterdam,) Tj ETQq1 1 0.784314 rgBT /Overlock	0.4	4
140	Physiological ligands of PPARs in inflammation and lipid homeostasis. Future Lipidology, 2006, 1, 191-201.	0.5	8
141	PPARs: Lipid Sensors that Regulate Cell Differentiation Processes. , 2006, , 117-131.		0
142	Functions of the Peroxisome Proliferator-Activated Receptor (PPAR) Î± and Î² in Skin Homeostasis, Epithelial Repair, and Morphogenesis. Journal of Investigative Dermatology Symposium Proceedings, 2006, 11, 30-35.	0.8	51
143	A Growth Hormone-Releasing Peptide that Binds Scavenger Receptor CD36 and Ghrelin Receptor Up-Regulates Sterol Transporters and Cholesterol Efflux in Macrophages through a Peroxisome Proliferator-Activated Receptor Î³-Dependent Pathway. Molecular Endocrinology, 2006, 20, 3165-3178.	3.7	69
144	Role of Prostacyclin versus Peroxisome Proliferator-Activated Receptor Î² Receptors in Prostacyclin Sensing by Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 242-246.	2.9	79

#	Article	IF	Citations
145	Peroxisome Proliferator-Activated Receptor-Î±-Null Mice Have Increased White Adipose Tissue Glucose Utilization, GLUT4, and Fat Mass: Role in Liver and Brain. Endocrinology, 2006, 147, 4067-4078.	2.8	73
146	Differentiation of Trophoblast Giant Cells and Their Metabolic Functions Are Dependent on Peroxisome Proliferator-Activated Receptor Î²/Î´. Molecular and Cellular Biology, 2006, 26, 3266-3281.	2.3	179
147	Reciprocal Regulation of Brain and Muscle Arnt-Like Protein 1 and Peroxisome Proliferator-Activated Receptor Î± Defines a Novel Positive Feedback Loop in the Rodent Liver Circadian Clock. Molecular Endocrinology, 2006, 20, 1715-1727.	3.7	317
148	Crosstalk between peroxisome proliferator-activated receptor Â and VEGF stimulates cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19069-19074.	7.1	170
149	International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors. Pharmacological Reviews, 2006, 58, 726-741.	16.0	869
150	The Fasting-induced Adipose Factor/Angiopoietin-like Protein 4 Is Physically Associated with Lipoproteins and Governs Plasma Lipid Levels and Adiposity. Journal of Biological Chemistry, 2006, 281, 934-944.	3.4	366
151	Involvement of PPAR nuclear receptors in tissue injury and wound repair. Journal of Clinical Investigation, 2006, 116, 598-606.	8.2	192
152	The G0/G1 switch gene 2 is a novel PPAR target gene. Biochemical Journal, 2005, 392, 313-324.	3.7	190
153	Decreased expression of peroxisome proliferatorâ€activated receptor Î± and liver fatty acid binding protein after partial hepatectomy of rats and mice. Liver International, 2005, 25, 33-40.	3.9	16
154	Kinase signaling cascades that modulate peroxisome proliferator-activated receptors. Current Opinion in Cell Biology, 2005, 17, 216-222.	5.4	61
155	PixFRET, an ImageJ plug-in for FRET calculation that can accommodate variations in spectral bleed-throughs. Microscopy Research and Technique, 2005, 68, 51-58.	2.2	193
156	Peroxisome Proliferator Activated Receptors. , 2005, , 267-280.		0
157	Pancreatic Islet Adaptation to Fasting Is Dependent on Peroxisome Proliferator-Activated Receptor Î± Transcriptional Up-Regulation of Fatty Acid Oxidation. Endocrinology, 2005, 146, 375-382.	2.8	89
158	PPARs in Diseases: Control Mechanisms of Inflammation. Current Medicinal Chemistry, 2005, 12, 2995-3009.	2.4	168
159	Peroxisome proliferator-activated receptor ?/? activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovascular Research, 2005, 65, 832-841.	3.8	154
160	Peroxisome Proliferator-Activated Receptor Î²/Î´ Exerts a Strong Protection from Ischemic Acute Renal Failure. Journal of the American Society of Nephrology: JASN, 2005, 16, 2395-2402.	6.1	102
161	Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferatorâ€"activated receptor-Î³. Journal of Experimental Medicine, 2005, 201, 1205-1215.	8.5	428
162	Peroxisome proliferator-activated receptor Î²/Î´ as a therapeutic target for metabolic diseases. Expert Opinion on Therapeutic Targets, 2005, 9, 861-873.	3.4	39

#	ARTICLE	IF	CITATIONS
163	Epithelium-Mesenchyme Interactions Control the Activity of Peroxisome Proliferator-Activated Receptor Î²/Î´ during Hair Follicle Development. Molecular and Cellular Biology, 2005, 25, 1696-1712.	2.3	57
164	Fluorescence Imaging Reveals the Nuclear Behavior of Peroxisome Proliferator-activated Receptor/Retinoid X Receptor Heterodimers in the Absence and Presence of Ligand*â™¦. Journal of Biological Chemistry, 2005, 280, 17880-17890.	3.4	106
165	Transcriptional Repression of Peroxisome Proliferator-activated Receptor Î²/Î´ in Murine Keratinocytes by CCAAT/Enhancer-binding Proteins*. Journal of Biological Chemistry, 2005, 280, 38700-38710.	3.4	42
166	Dosage-Dependent Effects of Akt1/Protein Kinase BÎ± (PKBÎ±) and Akt3/PKBÎ³ on Thymus, Skin, and Cardiovascular and Nervous System Development in Mice. Molecular and Cellular Biology, 2005, 25, 10407-10418.	2.3	196
167	Microsomal Triglyceride Transfer Protein Promotes the Secretion of Xenopus laevis Vitellogenin A1. Journal of Biological Chemistry, 2005, 280, 13902-13905.	3.4	32
168	Promoter Rearrangements Cause Species-specific Hepatic Regulation of the Glyoxylate Reductase/Hydroxypyruvate Reductase Gene by the Peroxisome Proliferator-activated Receptor Î±. Journal of Biological Chemistry, 2005, 280, 24143-24152.	3.4	21
169	Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. Journal of Steroid Biochemistry and Molecular Biology, 2005, 93, 99-105.	2.5	119
170	Nutrigenomics and nutrigenetics: the emerging faces of nutrition. FASEB Journal, 2005, 19, 1602-1616.	0.5	294
171	Genetic- or Transforming Growth Factor-Î²1-induced Changes in Epidermal Peroxisome Proliferator-activated Receptor Î²/Î´ Expression Dictate Wound Repair Kinetics. Journal of Biological Chemistry, 2005, 280, 18163-18170.	3.4	36
172	PPARs as Drug Targets to Modulate Inflammatory Responses?. Inflammation and Allergy: Drug Targets, 2004, 3, 361-375.	3.1	102
173	Be Fit or Be Sick: Peroxisome Proliferator-Activated Receptors Are Down the Road. Molecular Endocrinology, 2004, 18, 1321-1332.	3.7	196
174	Altered Growth in Male Peroxisome Proliferator-Activated Receptor Î³ (PPARÎ³) Heterozygous Mice: Involvement of PPARÎ³ in a Negative Feedback Regulation of Growth Hormone Action. Molecular Endocrinology, 2004, 18, 2363-2377.	3.7	35
175	Regional variations in ABC transporter expression along the mouse intestinal tract. Physiological Genomics, 2004, 17, 11-20.	2.3	52
176	The Direct Peroxisome Proliferator-activated Receptor Target Fasting-induced Adipose Factor (FIAF/PGAR/ANGPTL4) Is Present in Blood Plasma as a Truncated Protein That Is Increased by Fenofibrate Treatment. Journal of Biological Chemistry, 2004, 279, 34411-34420.	3.4	229
177	Impaired expression of NADH dehydrogenase subunit 1 and PPARÎ³ coactivator-1 in skeletal muscle of ZDF rats. Journal of Lipid Research, 2004, 45, 113-123.	4.2	55
178	Peroxisome proliferator-activated receptor Â is required in mature white and brown adipocytes for their survival in the mouse. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4543-4547.	7.1	336
179	Peroxisome proliferator-activated receptor-Î² as a target for wound healing drugs. Expert Opinion on Therapeutic Targets, 2004, 8, 39-48.	3.4	40
180	Peroxisome-Proliferator-Activated Receptor (PPAR)-Î³ Activation Stimulates Keratinocyte Differentiation. Journal of Investigative Dermatology, 2004, 123, 305-312.	0.7	175

#	Article	IF	Citations
181	The European dimension for the mouse genome mutagenesis program. Nature Genetics, 2004, 36, 925-927.	21.4	195
182	Peroxisome-proliferator-activated receptors and cancers: complex stories. Nature Reviews Cancer, 2004, 4, 61-70.	28.4	552
183	In vivo activation of PPAR target genes by RXR homodimers. EMBO Journal, 2004, 23, 2083-2091.	7.8	172
184	Essential role of Smad3 in the inhibition of inflammation-induced PPARÎ²/Î´ expression. EMBO Journal, 2004, 23, 4211-4221.	7.8	75
185	Lack of hypotriglyceridemic effect of gemfibrozil as a consequence of age-related changes in rat liver PPARÎ±. Biochemical Pharmacology, 2004, 67, 157-166.	4.4	40
186	Functions of peroxisome proliferator-activated receptors (PPAR) in skin homeostasis. Lipids, 2004, 39, 1093-1099.	1.7	47
187	PPARÎ± governs glycerol metabolism. Journal of Clinical Investigation, 2004, 114, 94-103.	8.2	207
188	PPARÎ± governs glycerol metabolism. Journal of Clinical Investigation, 2004, 114, 94-103.	8.2	121
189	Peroxisome proliferator-activated receptor-? as a target for wound healing drugs. Expert Opinion on Therapeutic Targets, 2004, 8, 39-48.	3.4	4
190	Understanding the Coordinated Effects of PPARs on Lipid Metabolism Using Microarrays. , 2004, , 249-263.		0
191	Peroxisome proliferator-activated receptor-Î² signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology, 2003, 124, 184-201.	1.3	120
192	The anti-apoptotic role of PPARÎ² contributes to efficient skin wound healing. Journal of Steroid Biochemistry and Molecular Biology, 2003, 85, 257-265.	2.5	66
193	Peroxisome Proliferator-Activated Receptor (PPAR)-?? as a Target for Wound Healing Drugs. American Journal of Clinical Dermatology, 2003, 4, 523-530.	6.7	33
194	PPARÎ² regulates vitamin A metabolism-related gene expression in hepatic stellate cells undergoing activation. Journal of Lipid Research, 2003, 44, 280-295.	4.2	58
195	Sex Difference in Hepatic Peroxisome Proliferator-Activated Receptor Î± Expression: Influence of Pituitary and Gonadal Hormones. Endocrinology, 2003, 144, 101-109.	2.8	113
196	Peroxisome proliferator-activated receptors Î²/Î´: emerging roles for a previously neglected third family member. Current Opinion in Lipidology, 2003, 14, 129-135.	2.7	50
197	Selective Cooperation between Fatty Acid Binding Proteins and Peroxisome Proliferator-Activated Receptors in Regulating Transcription. Molecular and Cellular Biology, 2002, 22, 5114-5127.	2.3	448
198	Differential Regulation of Vascular Endothelial Growth Factor Expression by Peroxisome Proliferator-activated Receptors in Bladder Cancer Cells. Journal of Biological Chemistry, 2002, 277, 23534-23543.	3.4	99

#	ARTICLE	IF	CITATIONS
199	A New Selective Peroxisome Proliferator-Activated Receptor Î³ Antagonist with Antiobesity and Antidiabetic Activity. Molecular Endocrinology, 2002, 16, 2628-2644.	3.7	201
200	PPAR-beta and retinol metabolism related gene-expression in HSC. Journal of Hepatology, 2002, 36, 71.	3.7	0
201	Antiapoptotic Role of PPARÎ² in Keratinocytes via Transcriptional Control of the Akt1 Signaling Pathway. Molecular Cell, 2002, 10, 721-733.	9.7	635
202	Peroxisome Proliferator Activated Receptor Alpha Coordinates Intermediary Metabolism During Fasting. Medical Science Symposia Series, 2002, , 1-4.	0.0	0
203	Sensors for Metabolic Control. Growth Hormone, 2002, , 283-304.	0.2	0
204	PPAR expression and function during vertebrate development. International Journal of Developmental Biology, 2002, 46, 105-14.	0.6	117
205	Peroxisome proliferator-activated receptors (PPARs): from metabolic control to epidermal wound healing. Swiss Medical Weekly, 2002, 132, 83-91.	1.6	77
206	Impaired skin wound healing in peroxisome proliferatorâ€"activated receptor (PPAR)Î± and PPARÎ² mutant mice. Journal of Cell Biology, 2001, 154, 799-814.	5.2	388
207	Critical roles of PPARbeta /delta in keratinocyte response to inflammation. Genes and Development, 2001, 15, 3263-3277.	5.9	373
208	Differential involvement of peroxisome-proliferator-activated receptors Î± and Î´ in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine. Biochemical Journal, 2001, 355, 481-488.	3.7	141
209	Attenuation of Colon Inflammation through Activators of the Retinoid X Receptor (Rxr)/Peroxisome Proliferatorâ€"Activated Receptor Î³ (PparÎ³) Heterodimer. Journal of Experimental Medicine, 2001, 193, 827-838.	8.5	416
210	The peroxisome proliferatorâ€activated receptor Î± regulates amino acid metabolism. FASEB Journal, 2001, 15, 1971-1978.	0.5	198
211	Rat PPARs: Quantitative Analysis in Adult Rat Tissues and Regulation in Fasting and Refeeding. Endocrinology, 2001, 142, 4195-4202.	2.8	433
212	Expression and Localization of PPARs in the Rat Ovary During Follicular Development and the Periovulatory Period. Endocrinology, 2001, 142, 4831-4838.	2.8	126
213	Differential involvement of peroxisome-proliferator-activated receptors Î± and Î´ in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine. Biochemical Journal, 2001, 355, 481.	3.7	99
214	Rat PPARs: Quantitative Analysis in Adult Rat Tissues and Regulation in Fasting and Refeeding. Endocrinology, 2001, 142, 4195-4202.	2.8	135
215	Roles of PPARs in health and disease. Nature, 2000, 405, 421-424.	27.8	1,782
216	Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2000, 448, 121-138.	1.0	414

#	ARTICLE	IF	CITATIONS
217	Characterization of the Fasting-induced Adipose Factor FIAF, a Novel Peroxisome Proliferator-activated Receptor Target Gene. Journal of Biological Chemistry, 2000, 275, 28488-28493.	3.4	481
218	Activation of Peroxisome Proliferator-Activated Receptors (PPARs) by Their Ligands and Protein Kinase A Activators. Molecular Endocrinology, 2000, 14, 1962-1975.	3.7	194
219	Determinants of Vitellogenin B1 Promoter Architecture. Journal of Biological Chemistry, 2000, 275, 28291-28300.	3.4	34
220	Nuclear Hormone Receptor Coregulators In Action: Diversity For Shared Tasks. Molecular Endocrinology, 2000, 14, 329-347.	3.7	350
221	Nuclear Hormone Receptors and Mouse Skin Homeostasis: Implication of PPARÎ². Hormone Research in Paediatrics, 2000, 54, 263-268.	1.8	10
222	An immuno-electron microscopical analysis of transcribing multinucleosomal templates: what happens to the histones? 1 1Edited by W. Baumeister. Journal of Molecular Biology, 2000, 299, 853-858.	4.2	13
223	Peroxisome proliferator activated receptor agonists. Exs, 2000, 89, 141-151.	1.4	65
224	Activation of Peroxisome Proliferator-Activated Receptors (PPARs) by Their Ligands and Protein Kinase A Activators. Molecular Endocrinology, 2000, 14, 1962-1975.	3.7	67
225	Nuclear Hormone Receptor Coregulators In Action: Diversity For Shared Tasks. Molecular Endocrinology, 2000, 14, 329-347.	3.7	118
226	Activation of the Mouse TATA-less and Human TATA-Containing UDP-Glucuronosyltransferase<i>1A1</i>Promoters by Hepatocyte Nuclear Factor 1. Molecular Pharmacology, 1999, 56, 526-536.	2.3	65
227	Chemical Probes That Differentially Modulate Peroxisome Proliferator-activated Receptor Î± and BLTR, Nuclear and Cell Surface Receptors for Leukotriene B4. Journal of Biological Chemistry, 1999, 274, 23341-23348.	3.4	43
228	Peroxisome Proliferator-activated Receptor Î² Regulates Acyl-CoA Synthetase 2 in Reaggregated Rat Brain Cell Cultures. Journal of Biological Chemistry, 1999, 274, 35881-35888.	3.4	114
229	Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. Current Opinion in Biotechnology, 1999, 10, 564-570.	6.6	184
230	Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*. Endocrine Reviews, 1999, 20, 649-688.	20.1	2,435
231	Ppars: Nuclear Receptors for Fatty Acids Eicosanoids, and Xenobiotics. Advances in Experimental Medicine and Biology, 1999, 469, 231-236.	1.6	26
232	Fatty Acids, Eicosanoids, and Hypolipidemic Agents Regulate Gene Expression Through Direct Binding to Peroxisome Proliferator-Activated Receptors. Advances in Experimental Medicine and Biology, 1999, 447, 199-209.	1.6	37
233	Peroxisome proliferatorâ€"activated receptor Î± mediates the adaptive response to fasting. Journal of Clinical Investigation, 1999, 103, 1489-1498.	8.2	1,423
234	The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling. Journal of Steroid Biochemistry and Molecular Biology, 1998, 65, 65-74.	2.5	83

#	ARTICLE	IF	CITATIONS
235	Do Peroxisome Proliferating Compounds Pose a Hepatocarcinogenic Hazard to Humans?. Regulatory Toxicology and Pharmacology, 1998, 27, 47-60.	2.7	212
236	Functional Interaction between the Estrogen Receptor and CTF1: Analysis of the Vitellogenin Gene B1 Promoter in Yeast. Molecular Endocrinology, 1998, 12, 1525-1541.	3.7	7
237	Differential Expression of Peroxisome Proliferator-Activated Receptor-Î±, -Î², and -Î³ during Rat Embryonic Development*. Endocrinology, 1998, 139, 2748-2754.	2.8	413
238	Functional Interaction between the Estrogen Receptor and CTF1: Analysis of the Vitellogenin Gene B1 Promoter in Yeast. Molecular Endocrinology, 1998, 12, 1525-1541.	3.7	1
239	PPARÎ±. , 1998, , 235-256.		0
240	Functional Interactions between the Estrogen Receptor and the Transcription Activator Sp1 Regulate the Estrogen-dependent Transcriptional Activity of the Vitellogenin A1 ioPromoter. Journal of Biological Chemistry, 1997, 272, 18250-18260.	3.4	64
241	Fatty Acids, Eicosanoids, and Hypolipidemic Agents Identified as Ligands of Peroxisome Proliferator-Activated Receptors by Coactivator-Dependent Receptor Ligand Assay. Molecular Endocrinology, 1997, 11, 779-791.	3.7	1,070
242	Polarity and Specific Sequence Requirements of Peroxisome Proliferator-activated Receptor (PPAR)/Retinoid X Receptor Heterodimer Binding to DNA. Journal of Biological Chemistry, 1997, 272, 20108-20117.	3.4	306
243	PPARÎ± Structure-Function Relationships Derived from Species-Specific Differences in Responsiveness to Hypolipidemic Agents. Biological Chemistry, 1997, 378, 651-656.	2.5	90
244	Transcriptional Regulation by Triiodothyronine of the UDP-glucuronosyltransferase Family 1 Gene Complex in Rat Liver. Journal of Biological Chemistry, 1997, 272, 17171-17175.	3.4	15
245	DNA Binding Properties of Peroxisome Proliferator-activated Receptor Subtypes on Various Natural Peroxisome Proliferator Response Elements. Journal of Biological Chemistry, 1997, 272, 25252-25259.	3.4	330
246	Steroid Hormone and Related Receptors. Principles of Medical Biology, 1997, , 255-296.	0.1	1
247	Retinoid X receptor and peroxisome proliferator-activated receptor activate an estrogen responsive gene independent of the estrogen receptor. Molecular and Cellular Endocrinology, 1997, 127, 27-40.	3.2	90
248	Peroxisome proliferator-activated receptor agonists. Current Opinion in Chemical Biology, 1997, 1, 235-241.	6.1	182
249	Fatty Acids, Eicosanoids, and Hypolipidemic Agents Identified as Ligands of Peroxisome Proliferator-Activated Receptors by Coactivator-Dependent Receptor Ligand Assay. Molecular Endocrinology, 1997, 11, 779-791.	3.7	384
250	PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS: A Nuclear Receptor Signaling Pathway in Lipid Physiology. Annual Review of Cell and Developmental Biology, 1996, 12, 335-363.	9.4	653
251	PPAR Tissue Distribution and Interactions with Other Hormone-Signaling Pathways. Annals of the New York Academy of Sciences, 1996, 804, 231-251.	3.8	149
252	The PPARÎ±â€“leukotriene B4 pathway to inflammation control. Nature, 1996, 384, 39-43.	27.8	1,329

#	Article	IF	Citations
253	Expression of the Peroxisome Proliferator-activated Receptor Î± Gene Is Stimulated by Stress and Follows a Diurnal Rhythm. Journal of Biological Chemistry, 1996, 271, 1764-1769.	3.4	291
254	Induction of the Acyl-Coenzyme A Synthetase Gene by Fibrates and Fatty Acids Is Mediated by a Peroxisome Proliferator Response Element in the C Promoter. Journal of Biological Chemistry, 1995, 270, 19269-19276.	3.4	344
255	Peroxisome Proliferator-activated Receptor Mediates Cross-talk with Thyroid Hormone Receptor by Competition for Retinoid X Receptor. Journal of Biological Chemistry, 1995, 270, 18117-18122.	3.4	143
256	Retinoid X Receptor Î² and Peroxisome Proliferator- Activated Receptor Activate an Estrogen Response Element. , 1995, 50, 409-416.		12
257	Peroxisome proliferator-activated receptors: finding the orphan a home. Molecular and Cellular Endocrinology, 1994, 100, 149-153.	3.2	161
258	Gene transfer into Xenopus hepatocytes: transcriptional regulation by members of the nuclear receptor superfamily. Molecular and Cellular Endocrinology, 1994, 101, 227-236.	3.2	6
259	Positive regulation of the peroxisomal Î²-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biology of the Cell, 1993, 77, 67-74.	2.0	253
260	Peroxisome proliferator-activated receptors A link between endocrinology and nutrition?. Trends in Endocrinology and Metabolism, 1993, 4, 291-296.	7.1	77
261	Peroxisome Proliferator-Activated Receptors and Lipid Metabolism. Annals of the New York Academy of Sciences, 1993, 684, 157-173.	3.8	83
262	Control of the peroxisomal Î²-oxidation pathway by a novel family of nuclear hormone receptors. Cell, 1992, 68, 879-887.	28.9	1,287
263	Superfamily of steroid nuclear receptors: positive and negative regulators of gene expression. FASEB Journal, 1991, 5, 2243-2249.	0.5	302
264	A Liver Protein Fraction Regulating Hormone-Dependentin VitroTranscription from the Vitellogenin Genes Induces Their Expression in Xenopus Oocytes. Molecular Endocrinology, 1991, 5, 159-169.	3.7	14
265	PCR driven DNA-DNA competitive hybridization: a new method for sensitive differential cloning. Nucleic Acids Research, 1991, 19, 4778-4778.	14.5	22
266	Ribosomal protein L27 is identical in chick and rat. Nucleic Acids Research, 1991, 19, 1337-1337.	14.5	23
267	Electron Microscope Visualisation of Protein-DNA Complexes. , 1991, , 153-161.		0
268	Identification of Two Steroid-Responsive Promoters of Different Strength Controlled by the Same Estrogen-Responsive Element in the 5â€²-End Region of theXenopus laevisVitellogenin Gene A1. Molecular Endocrinology, 1989, 3, 1596-1609.	3.7	5
269	Amphibian albumins as members of the albumin, alpha-fetoprotein, vitamin D-binding protein multigene family. Journal of Molecular Evolution, 1989, 29, 344-354.	1.8	55
270	Cis- and trans-acting elements of the estrogen-regulated vitellogenin gene B1 of Xenopus laevis. The Journal of Steroid Biochemistry, 1989, 34, 17-32.	1.1	27

#	Article	IF	Citations
271	Evolution and expression of vitellogenin genes. Trends in Genetics, 1988, 4, 227-232.	6.7	228
272	Immuno-electron microscopic identification of human estrogen receptor-DNA complexes at the estrogen-responsive element and in the first intron of a Xenopus vitellogenin gene. Journal of Molecular Biology, 1988, 204, 217-220.	4.2	10
273	The human estrogen receptor can regulate exogenous but not endogenous vitellogenin gene promoters in aXenopuscell line. Nucleic Acids Research, 1988, 16, 8291-8305.	14.5	30
274	Precursor-product relationship between vitellogenin and the yolk proteins as derived from the complete sequence of aXenopusvitellogenin gene. Nucleic Acids Research, 1987, 15, 4737-4760.	14.5	123
275	Vertebrate and nematode genes coding for yolk proteins are derived from a common ancestor. Biochemistry, 1987, 26, 6397-6402.	2.5	69
276	Complementary DNA cloning of complement C8.beta. and its sequence homology to C9. Biochemistry, 1987, 26, 3551-3556.	2.5	78
277	The distribution of the dinucleotide CpG and cytosine methylation in the vitellogenin gene family. Journal of Molecular Evolution, 1987, 25, 107-115.	1.8	16
278	Transposition of a bacterial IS3 element into aXenopusVi-element. Nucleic Acids Research, 1986, 14, 7814-7814.	14.5	1
279	Identification of estrogen-responsive DNA sequences by transient expression experiments in a human breast cancer cell line. Nucleic Acids Research, 1986, 14, 8755-8770.	14.5	178
280	Linkage arrangement in the vitellogenin gene family ofXenopus laevisas revealed by gene segregation analysis. Nucleic Acids Research, 1986, 14, 8723-8734.	14.5	24
281	The Vi element. Journal of Molecular Biology, 1985, 186, 491-503.	4.2	23
282	Evolution of vitellogeain genes: comparative analysis of the nucleotide sequences downstream of the transcription initiation site of fourXenopus laevisand one chicken gene. Nucleic Acids Research, 1984, 12, 8595-8609.	14.5	47
283	Sequence homologies in the region preceding the transcription initiation site of the liver estrogen-responsive vitellogenin and apo-VLDLII genes. Nucleic Acids Research, 1984, 12, 8611-8626.	14.5	254
284	Scattering of repetitive DNA sequences in the albumin and vitellogenin gene loci ofXenopus laevis. Nucleic Acids Research, 1983, 11, 7701-7716.	14.5	11
285	VlteBogtnin B2 gene inXenopus laevis: Isolation,in vitrotranscription and relation to other vitellogenin genes. Nucleic Acids Research, 1983, 11, 2979-2997.	14.5	44
286	Transcription of single-copy vitellogenin gene of Xenopus involves expression of middle repetitive DNA. Nature, 1981, 291, 429-431.	27.8	23
287	Isolation and Translation in vitro of Four Related Vitellogenin mRNAs of Estrogen-Stimulated Xenopus laevis. FEBS Journal, 1980, 105, 17-24.	0.2	39
288	Comparative analysis of the structural organization of two closely related vitellogenin genes in X. laevis. Cell, 1980, 20, 107-117.	28.9	110

#	Article	IF	Citations
289	Application of recombinant DNA technology to questions of developmental biology: A review. Developmental Biology, 1979, 69, 305-328.	2.0	63
290	Vitellogenin in Xenopus laevis is encoded in a small family of genes. Cell, 1979, 16, 535-549.	28.9	228
291	Retention of the differentiated state by larvalXenopus liver cells in primary culture. Wilhelm Roux's Archives of Developmental Biology, 1978, 185, 235-248.	1.4	8
292	Electron-Microscopic Demonstration of Terminal and Internal Initiation Sites for cDNA Synthesis on Vitellogenin mRNA. FEBS Journal, 1978, 86, 225-234.	0.2	22
293	Cloning and characterization of synthetic sequences from the Xenopus laevis vitellogenin structural gene. Developmental Biology, 1978, 67, 371-383.	2.0	61
294	Quantitation of vitellogenin messenger RNA in the liver of male xenopus toads during primary and secondary stimulation by estrogen. Cell, 1977, 11, 213-221.	28.9	107
295	Factors promoting the establishment of primary cultures of liver cells fromXenopus larvae. Wilhelm Roux's Archives of Developmental Biology, 1977, 182, 347-360.	1.4	4
296	Size, Complexity and Abundance of a Specific Poly(A)-Containing RNA of Liver from Male Xenopus Induced to Vitellogenin Synthesis by Estrogen. FEBS Journal, 1976, 66, 457-465.	0.2	65
297	PPARs: Nuclear Hormone Receptors Involved in the Control of Inflammation. , 0, , 419-435.		1
298	Peroxisomal Proliferator-Activated Receptor Î²/Î´ Deficiency Induces Cognitive Alterations. Frontiers in Pharmacology, 0, 13, .	3.5	2